PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Avelumab

Drugs in development · updated 30 October 2026

Avelumab: clinical trials and development status

Other names and codes: Bavencio

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 18 September 2017

As of 30 October 2026 Avelumab is in 58 active clinical trials (recruiting or ongoing, phases I–III) for 41 diseases. The most advanced phase is III.

58Active trials
IIIMost advanced phase
41Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Avelumab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 41 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Transitional cell carcinomaIII11NCT03815643
Bladder neoplasmIII7NCT05092958
Merkel cell carcinomaIII7NCT03271372
Head and neck squamous cell carcinomaIII6NCT02999087
Renal cell carcinomaIII5NCT03815643
Non-small-cell lung carcinomaIII3NCT03815643
Ureteral neoplasmIII3NCT05092958
Urethral neoplasmIII3NCT05092958
Head and neck neoplasmsIII2NCT02999087
Ovarian neoplasmIII2NCT05059522
Breast neoplasmII8NCT04841148
MetastasisII6NCT03391479
NeoplasmII5NCT04341181
MelanomaII4NCT03228667
Colorectal neoplasmII2NCT03228667
Endometrial neoplasmII2NCT06518564
Lung small cell carcinomaII2NCT06228066
Neuroendocrine tumorII2NCT04291885
Prostatic NeoplasmsI–II2NCT03217747
Skin neoplasmII2NCT03944941
Stomach neoplasmII2NCT03228667
Triple-negative breast neoplasmII2NCT03971409
CarcinomaI–II1NCT04261855
CholangiocarcinomaI–II1NCT04068194
Chronic phase chronic myelogenous leukemiaI–II1NCT02767063
Gallbladder neoplasmI–II1NCT04068194
Hepatocellular carcinomaII1NCT03228667
Lymphatic metastasisI–II1NCT04071236
Microsatellite instabilityII1NCT03228667
Penile neoplasmII1NCT03391479

Everything on Avelumab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch